ORLANDO, Fla., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that initial studies indicate that a new blood test using the Company’s proprietary antibody, clivatuzumab (PAM4), may identify patients with early-stage pancreatic cancer. Results were presented in a presscast as part of the seventh annual Gastrointestinal (GI) Cancers Symposium in Orlando, Florida, by Dr. David V. Gold of the Garden State Cancer Center, in Belleville, New Jersey, who was the developer of clivatuzumab. The blood assay for PAM4-protein was evaluated in 68 patients who had pancreatic cancer surgery and in 19 healthy controls. It was found that the test was 62% sensitive for detecting stage-1 pancreatic cancer (disease confined to pancreas), 86% for stage 2 disease, and 91% for stage 3/4 (local and distant spread) cancers.
